Search clinical trials for: branded formulation of atorvastatin (Lipitor®)

Total 406 results

Seoul National University Hospital
Yuhan corp., Seoul, Korea

Completed

The Efficacy and Safety of Atorva® 20mg Versus Lipitor® 20mg

Hypercholesterolemia

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

Dyslipidemia in Cardiovascular Disease (KoLipilou)

Dyslipidemia
Makerere University
Vaccine and Gene Therapy Institute, Florida

Completed

Atorvastatin for HAART Suboptimal Responders

Acquired Immune Deficiency Syndrome Virus
Chong Kun Dang Pharmaceutical

Completed

CKD-391 DDI : Atorvastatin and Ezetimibe in Healthy Volunteers

Healthy

Korea, Republic of
Seoul National University Hospital
Dong-A Pharmaceutical

Completed

The Efficacy and Tolerability of Two Formulations of Atorvastatin In Korean Adult With Hypercholesterolemia

Cardiovascular Disease | Dyslipidemia | Hypercholesterolemia

Korea, Republic of
Laboratorios Silanes S.A. de C.V.

Recruiting

Efficacy and Safety of the Fixed-dose Combination Atorvastatin/Fenofibrate vs Atorvastatin in Patients With T2D and DLP.

Dyslipidemia Associated With Type II Diabetes Mellitus

Mexico
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

Bioequivalence Study On Pediatric Appropriate Formulation

Hypercholesterolemia

Singapore
Chong Kun Dang Pharmaceutical

Completed

Clinical Trial to to Compare of the Efficacy and Safety of Lipilou® 20 mg and Lipilou® 10 mg

Hypercholesterolemia

Korea, Republic of
Organon and Co

Completed

A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/40 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 40 mg Tablets in Participants With High Cholesterol (MK-0653C-190 AM1)

Hypercholesterolemia
Wakayama Medical University

Completed

Change in Plaque Characteristics With Atorvastatin (EASY-FIT)

Atherosclerosis | Dyslipidemia | Acute Coronary Syndrome

Japan
Organon and Co

Completed

A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/20 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 20 mg Tablets in Participants With High Cholesterol (MK-0653C-185 AM1)

Hypercholesterolemia
Samsung Medical Center

Unknown

Efficacy Study of Atorvastatin to Treat Variant Angina (ESAVA)

Angina Pectoris, Variant

Korea, Republic of
Astellas Pharma Inc

Completed

Special Drug Use-Results Survey of Lipitor Tablets (ALWAYS)

Hypercholesterolemia

Japan
Shanghai Jiao Tong University School of Medicine

Unknown

Atorvastatin Plus Ezetimibe on Coronary Plaque Progression (AEPP)

Coronary Artery Disease

China
Organon and Co

Completed

An Efficacy and Safety Study of Ezetimibe (MK-0653, SCH 58235) in Addition to Atorvastatin Compared to Placebo in Participants With Primary Hypercholesterolemia (MK-0653-013)

Hypercholesterolemia
The Cleveland Clinic
Pfizer

Terminated

The Effect of Lipitor on Aortic Stenosis

Aortic Valve Stenosis

United States
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID); Pfizer

Completed

Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells

HIV-1 Infection

United States, Puerto Rico
Massachusetts Eye and Ear Infirmary

Recruiting

Dark Adaptation as an Early Indicator of Response to Statin Therapy for Intermediate AMD (DELPHI)

Age-related Macular Degeneration

United States
Organon and Co

Completed

Ezetimibe Plus (+) Simvastatin Versus Atorvastatin Comparative Study (0653A-092)(COMPLETED)

Hypercholesterolemia
Organon and Co

Completed

Vytorin (10/20 Or 10/40) Compared to Atorvastatin (10 mg or 20 mg) in Patients With Coronary Artery Disease (0653A-126)(COMPLETED)

Hypercholesterolemia
Mayo Clinic

Completed

Statin Interchange by Pharmacist Collaborative Practice Agreement (CPA)

Hypercholesterolemia

United States
Organon and Co

Completed

A Multicenter, Randomized, Open Label Study to Evaluate the Lipid Lowering Efficacy and Safety of Vytorin® 10/20 vs. Atorvastatin 10mg in Hypercholesterolemia Patients With Metabolic Syndrome in Korea (0653A-129)(COMPLETED)

Hypercholesterolemia
Organon and Co

Completed

Ezetimibe (+) Simvastatin vs. Atorvastatin Comparative Study in DM or Metabolic Syndrome Patients (0653A-093)

Hypercholesterolemia
Kumamoto University

Completed

Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound (PRECISE-IVUS)

Coronary Artery Disease | Hypercholesterolemia

Japan
Peking Union Medical College
Chinese Academy of Medical Sciences, Fuwai Hospital

Completed

Safety and Efficiency Study of Loading Dose Atorvastatin in Cardiac Surgery

Acute Kidney Injury

China
Dong-A ST Co., Ltd.

Unknown

Bioequivalence Study Between "Dong-A Atorvastatin Tab" and "Lipitor Tab"

Healthy

Korea, Republic of
Xijing Hospital

Unknown

Ezetimibe and Atorvastatin Therapy on TCFA

Coronary Artery Disease

China
The Catholic University of Korea
Jeil Pharmaceutical Co., Ltd.

Terminated

The Effect of Atorvastatin and Pioglitazone on Carotid Atherosclerosis With the Use of Positron Emission Tomography-computed Tomography (PET-CT) (PIONEER)

Coronary Artery Disease | Atherosclerosis

Korea, Republic of
Bavarian Nordic

Completed

A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects

Smallpox

United States
St. Olavs Hospital
Ullevaal University Hospital; Oslo University Hospital; University Hospital of... and other collaborators

Not yet recruiting

Prophylactic Treatment With Atorvastatin for Episodic Migraine. (EStatinMig)

Episodic Migraine
University of Kansas Medical Center
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Completed

Impact of Statin Therapy on Muscle Mitochondrial Function and Aerobic Capacity

Mitochondrial Diseases

United States
National Cardiovascular Center Harapan Kita Hospital...

Completed

Effect of 80-mg Atorvastatin on Myocardial Edema

Myocardial Edema
Wenzhou Medical University

Recruiting

The Efficacy and Safety of Combined Therapy With Red Yeast Rice and Low-dose Statin：Comparing With Standardized Statin

Atherosclerosis | Dyslipidemia

China
Organon and Co

Completed

Efficacy and Safety Study of Ezetimibe (SCH 58235, MK-0653) in Addition to Atorvastatin in Participants With Coronary Heart Disease or Multiple Cardiovascular Risk Factors (P00693/MK-0653-030)

Hypercholesterolemia
Beijing Hospital

Unknown

High Dose Atorvastatin for Preventing Periprocedural Ischemic Brain Damage During Carotid Artery Stenting (PICAS)

Carotid Artery Stenosis

China
Creighton University

Unknown

Intensive Statin Therapy Effect on Post-Operative Atrial Fibrillation (POAF)

Cardiothoracic Surgery | Post-operative Atrial Fibrillation

United States
Ottawa Hospital Research Institute
Heart and Stroke Foundation of Ontario; Canadian Anesthesiologists' Society

Completed

Statin Drugs to Prevent Complications During Surgery (STAR-VaS)

Myocardial Infarction | Myocardial Ischemia | Inflammation

Canada
Brooke Army Medical Center

Completed

Efficacy of Actos Lipitor Pegasys & Ribavirin in CHC GT 1 Patients Who Relapsed or Nonresponded to Peg/Riba

Hepatitis c

United States
Hormozgan University of Medical Sciences

Completed

High Dose and Low Dose of Atorvastatin in Patients With Unstable Angina and NSTEMI (Non ST Elevation MI)

Cardiovascular Disease

Iran, Islamic Republic of
University of North Carolina, Chapel Hill
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Effect of Atorvastatin on Endothelial Dysfunction and Albuminuria in Sickle Cell Disease (ENDO)

Sickle Cell Disease | Sickle Cell Nephropathy

United States
Merck Sharp & Dohme LLC

Completed

A Study of MK-6213 Co-Administered With Atorvastatin in Participants With Hypercholesterolemia (MK-6213-006)

Hypercholesterolemia
Central South University

Unknown

Atorvastatin for Reduction of Myocardial Damage During Angiography and Its Mechanism Associated With IMR (ARMYDA-IMR)

Stable Angina | Unstable Angina | Acute Non-ST-segment Elevation Myocardial Infarction

China
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets (ACTFAST 2)

Diabetes Mellitus, Type 2 | Dyslipidemia | Peripheral Vascular Disease | Coronary Arteriosclerosis | Cerebrovascular Accident

Greece, Ireland, Russian Federation, Slovakia, Poland, Hungary, Portugal, Switzerland
University of Oslo School of Pharmacy

Completed

Association Between Systemic Exposure of Atorvastatin and Metabolites and Atorvastatin-induced Myotoxicity

Myopathy
University of Chicago

Completed

Use of Atorvastatin (Lipitor) to Decrease Panel Reactive Antibody Titers

End-Stage Kidney Disease

United States
Radboud University Medical Center
Pfizer

Completed

Does Atorvastatin Reduce Ischemia-Reperfusion Injury in Humans in-Vivo?

Cardiovascular Disease | Ischemia Reperfusion Injury

Netherlands
Sheba Medical Center

Withdrawn

Assessment of Endothelial Function in Patients With Non Alcoholic Fatty Liver Disease and the Impact of Statin Treatment

Non Alcoholic Fatty Liver Disease

Israel
Baylor College of Medicine
The University of Texas Health Science Center, Houston

Terminated

Mission Connect Mild Traumatic Brain Injury (TBI) Integrated Clinical Protocol

Traumatic Brain Injury | Post-traumatic Stress Disorder

United States
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

Establish The Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets (ACTFAST) (ACTFAST)

Diabetes Mellitus, Type 2 | Dyslipidemia | Peripheral Vascular Disease | Coronary Arteriosclerosis | Cerebrovascular Accident

Italy, Spain, Canada, United Kingdom, Cameroon
Astellas Pharma Inc

Completed

Lipitor Phase 4 Clinical Trial in Hypercholesteremia Patients With Yellow Coronary Plaque

Coronary Artery Disease | Hypercholesteremia

Japan

Search clinical trials for: branded formulation of atorvastatin (Lipitor®)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Romania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations